Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications
Autonomix Medical, a medical device company dedicated to advancing precision nerve-targeted treatments, announced the United States Patent and Trademark Office has issued U.S. Patent No. 12,279,889 B2 (the ‘889 patent) titled, “Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification.” The newly issued ‘899 patent relates to but is not limited to advanced systems and methods for locating, monitoring and mapping electrophysiological signals before, during and following a neuromodulation or denervation procedures. Furthermore, the patent explicitly contemplates tools to access small vessels and navigation to the target area to treat cancerous tumors and the pain associated with cancerous tumors. The technology is designed to treat conditions influenced by sympathetic nerve activity, including renal denervation for hypertension, chronic pain syndromes, cardiac modulation and metabolic and neurological disorders.
Health Technology Insights: Craft Telemedicine Launches to Redefine Specialty Care with Human-Centered Platform
“This granted patent represents a significant step forward in our mission to improve patient outcomes by delivering more effective, less invasive treatments for conditions involving the nervous system, including chronic pain, autonomic dysfunction associated with hypertension and a range of other nerve-related disorders. We are pleased to strengthen our IP portfolio and further enhance our intellectual property position in the rapidly growing nerve-focused therapeutics space, enabling us to protect our innovations and deliver improved solutions for both clinicians and patients,” commented Brad Hauser, CEO of Autonomix.
Health Technology Insights: Gold Coast Health Plan Awards Grants to Expand Ventura Care
In particular, the ‘899 patent describes the Autonimix technology including, but not limited to: use of sensors integrated into microneedles for deep tissue access; multiband optical sensors for tissue viability and tone; microfingers for gentle, reliable contact and distributed sensing; and control systems that automatically adjust treatment based on feedback signals.
Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.
The Company expects to submit an Investigational Device Exemption (IDE) and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.
Health Technology Insights: Anderson Longevity Clinic Launches Nationwide Medical Clinic Franchise
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobeNewswire
